Manuscripts and Publications

Filters: Author is Labaki, Wassim W  [Clear All Filters]
2022
Godbole S, Labaki WW, Pratte KA, Hill A, Moll M, Hastie AT, Peters SP, Gregory A, Ortega VE, Demeo D et al..  2022.  A Metabolomic Severity Score for Airflow Obstruction and Emphysema.. Metabolites. 12(5)
2021
Burkes RM, Couper DJ, Barjaktarevic IZ, Cooper CB, Labaki WW, Han MK, Woodruff PG, Lazarus SC, Parekh TM, Paine R et al..  2021.  Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS.. Chronic Obstr Pulm Dis. 8(2):277-291.
Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, J Wells M et al..  2021.  Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.. Respir Res. 22(1):126.
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.
2020
Zhang WZ, Rice MC, Hoffman KL, Oromendia C, Barjaktarevic IZ, J Wells M, Hastie AT, Labaki WW, Cooper CB, Comellas AP et al..  2020.  Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. JCI Insight. 5(3)
Burkes RM, Ceppe AS, Doerschuk CM, Couper D, Hoffman EA, Comellas AP, R Barr G, Krishnan JA, Cooper C, Labaki WW et al..  2020.  Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort.. Chest. 157(4):856-865.
Burkes RM, Ceppe AS, Couper DJ, Comellas AP, J Wells M, Peters SP, Criner GJ, Kanner RE, Paine R, Christenson SA et al..  2020.  Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Chronic Obstr Pulm Dis. 7(4):370-381.
Gillenwater LA, Pratte KA, Hobbs BD, Cho MH, Zhuang Y, Halper-Stromberg E, Cruickshank-Quinn C, Reisdorph N, Petrache I, Labaki WW et al..  2020.  Plasma Metabolomic Signatures of Chronic Obstructive Pulmonary Disease and the Impact of Genetic Variants on Phenotype-Driven Modules.. Netw Syst Med. 3(1):159-181.
2019
Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE et al..  2019.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.. Chest. 155(3):519-527.
Halper-Stromberg E, Gillenwater L, Cruickshank-Quinn C, O'Neal WKay, Reisdorph N, Petrache I, Zhuang Y, Labaki WW, Curtis JL, Wells J et al..  2019.  Bronchoalveolar Lavage Fluid from COPD Patients Reveals More Compounds Associated with Disease than Matched Plasma.. Metabolites. 9(8)
J Wells M, Xing D, Viera L, Burkes RM, Wu Y, Bhatt SP, Dransfield MT, Couper DJ, O'Neal W, Hoffman EA et al..  2019.  The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS.. Respir Res. 20(1):254.
Labaki WW, Gu T, Murray S, Curtis JL, Yeomans L, Bowler RP, R Barr G, Comellas AP, Hansel NN, Cooper CB et al..  2019.  Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study.. Sci Rep. 9(1):11367.
2018
Fawzy A, Putcha N, Paulin LM, Aaron CP, Labaki WW, Han MK, Wise RA, Kanner RE, Bowler RP, R Barr G et al..  2018.  Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts.. Respir Res. 19(1):20.
Bhatt SP, Nath HP, Kim Y-I, Ramachandran R, Watts JR, Terry NLJ, Sonavane S, Deshmane SP, Woodruff PG, Oelsner EC et al..  2018.  Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort.. Respir Res. 19(1):257.
J Wells M, Parker MM, Oster RA, Bowler RP, Dransfield MT, Bhatt SP, Cho MH, Kim V, Curtis JL, Martinez FJ et al..  2018.  Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene.. JCI Insight. 3(22)
Labaki WW, Xia M, Murray S, Curtis JL, R Barr G, Bhatt SP, Bleecker ER, Hansel NN, Cooper CB, Dransfield MT et al..  2018.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.. Respir Med. 140:87-93.